Literature DB >> 33597948

CD8+CD161+ T-Cells: Cytotoxic Memory Cells With High Therapeutic Potential.

Vanaja Konduri1, Damilola Oyewole-Said1, Jonathan Vazquez-Perez1, Scott A Weldon2, Matthew M Halpert1, Jonathan M Levitt1,3,4, William K Decker1,3,5.   

Abstract

NK1.1 and its human homolog CD161 are expressed on NK cells, subsets of CD4+ and CD8+ T cells, and NKT cells. While the expression of NK1.1 is thought to be inhibitory to NK cell function, it is reported to play both costimulatory and coinhibitory roles in T-cells. CD161 has been extensively studied and characterized on subsets of T-cells that are MR1-restricted, IL-17 producing CD4+ (TH17 MAIT cells) and CD8+ T cells (Tc17 cells). Non-MAIT, MR1-independent CD161-expressing T-cells also exist and are characterized as generally effector memory cells with a stem cell like phenotype. Gene expression analysis of this enigmatic subset indicates a significant enhancement in the expression of cytotoxic granzyme molecules and innate like stress receptors in CD8+NK1.1+/CD8+CD161+ cells in comparison to CD8+ cells that do not express NK1.1 or CD161. First identified and studied in the context of viral infection, the role of CD8+CD161+ T-cells, especially in the context of tumor immunology, is still poorly understood. In this review, the functional characteristics of the CD161-expressing CD8+ T cell subset with respect to gene expression profile, cytotoxicity, and tissue homing properties are discussed, and application of this subset to immune responses against infectious disease and cancer is considered.
Copyright © 2021 Konduri, Oyewole-Said, Vazquez-Perez, Weldon, Halpert, Levitt and Decker.

Entities:  

Keywords:  CD161; KLRB1; T-cell; TH1 polarization; effector memory

Year:  2021        PMID: 33597948      PMCID: PMC7882609          DOI: 10.3389/fimmu.2020.613204

Source DB:  PubMed          Journal:  Front Immunol        ISSN: 1664-3224            Impact factor:   7.561


  82 in total

Review 1.  MAIT cells in infectious diseases.

Authors:  Marion Salou; Katarzyna Franciszkiewicz; Olivier Lantz
Journal:  Curr Opin Immunol       Date:  2017-07-24       Impact factor: 7.486

2.  A subset of virus-specific CD161+ T cells selectively express the multidrug transporter MDR1 and are resistant to chemotherapy in AML.

Authors:  Abdullah Alsuliman; Muharrem Muftuoglu; Ahmad Khoder; Yong-Oon Ahn; Rafet Basar; Michael R Verneris; Pawel Muranski; A John Barrett; Enli Liu; Li Li; Kate Stringaris; Darius Armstrong-James; Hila Shaim; Kayo Kondo; Nobuhiko Imahashi; Borje Andersson; David Marin; Richard E Champlin; Elizabeth J Shpall; Katayoun Rezvani
Journal:  Blood       Date:  2016-11-07       Impact factor: 22.113

3.  Cutting edge: lectin-like transcript-1 is a ligand for the inhibitory human NKR-P1A receptor.

Authors:  David B Rosen; Jayaram Bettadapura; Mohammed Alsharifi; Porunelloor A Mathew; Hilary S Warren; Lewis L Lanier
Journal:  J Immunol       Date:  2005-12-15       Impact factor: 5.422

4.  Dissecting CD8+ NKT Cell Responses to Listeria Infection Reveals a Component of Innate Resistance.

Authors:  Sergey S Seregin; Grace Y Chen; Yasmina Laouar
Journal:  J Immunol       Date:  2015-06-26       Impact factor: 5.422

5.  Tc17, a unique subset of CD8 T cells that can protect against lethal influenza challenge.

Authors:  Hiromasa Hamada; Maria de la Luz Garcia-Hernandez; Joyce B Reome; Sara K Misra; Tara M Strutt; Kai K McKinstry; Andrea M Cooper; Susan L Swain; Richard W Dutton
Journal:  J Immunol       Date:  2009-03-15       Impact factor: 5.422

6.  Missing self-recognition of Ocil/Clr-b by inhibitory NKR-P1 natural killer cell receptors.

Authors:  James R Carlyle; Amanda M Jamieson; Stephan Gasser; Christopher S Clingan; Hisashi Arase; David H Raulet
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-27       Impact factor: 11.205

Review 7.  Beyond ecto-nucleotidase: CD39 defines human Th17 cells with CD161.

Authors:  Aiping Bai; Simon Robson
Journal:  Purinergic Signal       Date:  2015-06-10       Impact factor: 3.765

8.  Intratumoral HPV16-Specific T Cells Constitute a Type I-Oriented Tumor Microenvironment to Improve Survival in HPV16-Driven Oropharyngeal Cancer.

Authors:  Marij J P Welters; Wenbo Ma; Saskia J A M Santegoets; Renske Goedemans; Ilina Ehsan; Ekaterina S Jordanova; Vanessa J van Ham; Vincent van Unen; Frits Koning; Sylvia I van Egmond; Pornpimol Charoentong; Zlatko Trajanoski; Lilly-Ann van der Velden; Sjoerd H van der Burg
Journal:  Clin Cancer Res       Date:  2017-10-10       Impact factor: 12.531

9.  Induction of lectin-like transcript 1 (LLT1) protein cell surface expression by pathogens and interferon-γ contributes to modulate immune responses.

Authors:  Claire Germain; Anders Meier; Teis Jensen; Perrine Knapnougel; Gwenola Poupon; Anne Lazzari; Anne Neisig; Katarina Håkansson; Tao Dong; Nicolai Wagtmann; Elizabeth D Galsgaard; Pieter Spee; Veronique M Braud
Journal:  J Biol Chem       Date:  2011-09-19       Impact factor: 5.157

10.  CD161 (NKR-P1A) costimulation of CD1d-dependent activation of human T cells expressing invariant V alpha 24 J alpha Q T cell receptor alpha chains.

Authors:  M Exley; S Porcelli; M Furman; J Garcia; S Balk
Journal:  J Exp Med       Date:  1998-09-07       Impact factor: 14.307

View more
  16 in total

1.  Self-reactive, innate-like T cells enhance cytotoxicity and immunosurveillance.

Authors:  Blaire E Barton; Cindy H Chau; William D Figg
Journal:  Trends Cancer       Date:  2022-06-04

Review 2.  Advances in NK cell production.

Authors:  Fang Fang; Siqi Xie; Minhua Chen; Yutong Li; Jingjing Yue; Jie Ma; Xun Shu; Yongge He; Weihua Xiao; Zhigang Tian
Journal:  Cell Mol Immunol       Date:  2022-01-05       Impact factor: 22.096

3.  Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8+ T cell responses.

Authors:  Karl L Banta; Xiaozheng Xu; Avantika S Chitre; Amelia Au-Yeung; Chikara Takahashi; William E O'Gorman; Thomas D Wu; Stephanie Mittman; Rafael Cubas; Laetitia Comps-Agrar; Amit Fulzele; Eric J Bennett; Jane L Grogan; Enfu Hui; Eugene Y Chiang; Ira Mellman
Journal:  Immunity       Date:  2022-03-08       Impact factor: 43.474

4.  NK Cells and Innate-Like T Cells After Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis.

Authors:  Josefine Ruder; Jordan Rex; Simon Obahor; María José Docampo; Antonia M S Müller; Urs Schanz; Ilijas Jelcic; Roland Martin
Journal:  Front Immunol       Date:  2021-12-16       Impact factor: 7.561

5.  Systematic Pan-Cancer Analysis of KLRB1 with Prognostic Value and Immunological Activity across Human Tumors.

Authors:  Xin Cheng; Yucheng Cao; Xiaowei Wang; Lin Cheng; Yaqiong Liu; Jun Lei; Weijun Peng; Dazun Shi
Journal:  J Immunol Res       Date:  2022-01-03       Impact factor: 4.818

Review 6.  Glioma targeted therapy: insight into future of molecular approaches.

Authors:  Keyang Yang; Zhijing Wu; Hao Zhang; Nan Zhang; Wantao Wu; Zeyu Wang; Ziyu Dai; Xun Zhang; Liyang Zhang; Yun Peng; Weijie Ye; Wenjing Zeng; Zhixiong Liu; Quan Cheng
Journal:  Mol Cancer       Date:  2022-02-08       Impact factor: 27.401

7.  CD161 expression defines new human γδ T cell subsets.

Authors:  John J Miles; Champa N Ratnatunga; Amali Karunathilaka; Samuel Halstrom; Patricia Price; Michael Holt; Viviana P Lutzky; Denise L Doolan; Andreas Kupz; Scott C Bell; Rachel M Thomson
Journal:  Immun Ageing       Date:  2022-02-22       Impact factor: 6.400

8.  Chronic Inflammation Might Protect Hemodialysis Patients From Severe COVID-19.

Authors:  Barbara Prietl; Balazs Odler; Alexander H Kirsch; Katharina Artinger; Manfred Eigner; Sabine Schmaldienst; Verena Pfeifer; Stefanie Stanzer; Anita Eberl; Reingard Raml; Thomas Pieber; Alexander R Rosenkranz; Marianne Brodmann; Philipp Eller; Kathrin Eller
Journal:  Front Immunol       Date:  2022-02-21       Impact factor: 7.561

9.  Reprogramming and redifferentiation of mucosal-associated invariant T cells reveal tumor inhibitory activity.

Authors:  Chie Sugimoto; Yukie Murakami; Eisuke Ishii; Hiroyoshi Fujita; Hiroshi Wakao
Journal:  Elife       Date:  2022-04-05       Impact factor: 8.713

10.  A Pan-Cancer Analysis of CD161, a Potential New Immune Checkpoint.

Authors:  Xiaohan Zhou; Jun Du; Chengdong Liu; Hanyi Zeng; Yuting Chen; Li Liu; Dehua Wu
Journal:  Front Immunol       Date:  2021-07-09       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.